ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-5.04%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$497M
AUM Growth
+$497M
(+36%)
Cap. Flow
+$71.1M
Cap. Flow
% of AUM
14.31%
Top 10 Holdings %
Top 10 Hldgs %
61.21%
Holding
306
New
59
Increased
87
Reduced
47
Closed
53
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29M |
| 2 |
Protagonist Therapeutics
PTGX
|
$28.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$18.1M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
Royalty Pharma
RPRX
|
$12.1M |
Top Sells
| 1 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$59.3M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$43.3M |
| 3 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$13.3M |
| 4 |
Perspective Therapeutics
CATX
|
$6.05M |
| 5 |
Sarepta Therapeutics
SRPT
|
$4.21M |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Financials | 1.87% |
| 3 | Industrials | 0.23% |
| 4 | Utilities | 0.18% |
| 5 | Materials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insmed
INSM
$30.3B
| $2.83M | 0.53% |
+42,217
| New | +$2.83M |
|
27
Q32 Bio
QTTB
$20.6M
| $2.81M | 0.53% |
156,504
-31,063
| -17% | -$558K |
|
|
GRCE
28
Grace Therapeutics, Inc. Common Stock
GRCE
$40.7M
| $2.8M | 0.53% |
959,571
+742,190
| +341% | +$2.17M |
|
29
Vanguard Ultra-Short Bond ETF
VUSB
$5.46B
| $2.73M | 0.52% |
55,206
| – | – |
|
30
JPMorgan Ultra-Short Income ETF
JPST
$33B
| $2.73M | 0.51% |
54,000
| – | – |
|
31
iShares Short Treasury Bond ETF
SHV
$20.7B
| $2.71M | 0.51% |
24,500
| – | – |
|
32
Savara
SVRA
$582M
| $2.67M | 0.5% |
663,598
+657,998
| +11,750% | +$2.65M |
|
33
OmniAb
OABI
$223M
| $2.67M | 0.5% |
712,560
+261,075
| +58% | +$979K |
|
34
WisdomTree Floating Rate Treasury Fund
USFR
$18.8B
| $2.67M | 0.5% |
53,000
| – | – |
|
35
Achieve Life Sciences
ACHV
$147M
| $2.55M | 0.48% |
542,233
-332,767
| -38% | -$1.56M |
|
|
CNTA
36
Centessa Pharmaceuticals
CNTA
$2.05B
| $2.29M | 0.43% |
253,197
+46,341
| +22% | +$418K |
|
37
Fulcrum Therapeutics
FULC
$348M
| $2.28M | 0.43% |
368,369
+28,544
| +8% | +$177K |
|
38
KALA BIO
KALA
$96.9M
| $2.17M | 0.41% |
+306,067
| New | +$2.17M |
|
39
Kiniksa Pharmaceuticals
KNSA
$2.6B
| $2.13M | 0.4% |
114,309
+54,609
| +91% | +$1.02M |
|
40
SPDR SSGA Ultra Short Term Bond ETF
ULST
$613M
| $1.93M | 0.36% |
47,684
| – | – |
|
41
Beam Therapeutics
BEAM
$1.85B
| $1.71M | 0.32% |
+72,800
| New | +$1.71M |
|
42
Cellectar Biosciences
CLRB
$15.4M
| $1.71M | 0.32% |
682,094
+39,553
| +6% | +$98.9K |
|
43
Teva Pharmaceuticals
TEVA
$21.5B
| $1.68M | 0.32% |
103,121
+1,495
| +1% | +$24.3K |
|
44
Delcath Systems
DCTH
$383M
| $1.66M | 0.31% |
198,347
-20,626
| -9% | -$173K |
|
45
Soleno Therapeutics
SLNO
$3.52B
| $1.63M | 0.31% |
+39,929
| New | +$1.63M |
|
46
Apogee Therapeutics
APGE
$2.27B
| $1.61M | 0.3% |
40,875
+34,875
| +581% | +$1.37M |
|
47
Merus
MRUS
$5.03B
| $1.59M | 0.3% |
+26,850
| New | +$1.59M |
|
|
ONC
48
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.1B
| $1.58M | 0.3% |
11,100
-20,405
| -65% | -$2.91M |
|
49
Aura Biosciences
AURA
$391M
| $1.54M | 0.29% |
+203,237
| New | +$1.54M |
|
50
Kymera Therapeutics
KYMR
$3.03B
| $1.51M | 0.29% |
50,626
+34,626
| +216% | +$1.03M |
|